Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Novo Nordisk has been on the hunt for differentiated obesity drugs that could complement its blockbuster GLP-1 agonist, Wegovy. It’s found a contender with preclinical data indicating it can ...

Novo Nordisk's GLP-1 receptor agonist ... The topline results from the ESSENCE trial of semaglutide showed that a once-weekly 2.4mg dose of the drug was better than placebo at resolving MASH ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy, Novo Nordisk has ... announce an FDA new drug submission.

Shares of Novo Nordisk slipped in Monday morning ... 61.9% of patients were given the highest dose of the drug, which combines the GLP-1 agonist semaglutide, the active ingredient in Wegovy ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ... to access to its Wegovy (semaglutide) injection 0.25 mg, 0.5 ...

Packets of Wegovy move along the line at the Novo Nordisk A/S production ... obesity treatment known as Contrave. Semaglutide is the compound in the drugs Ozempic, which treats diabetes, and ...